SGLT2 inhibitors and GLP1-receptor agonists reduce CHD risk in diabetes patients: Study
Italy: Both SGLT2 inhibitors and GLP1-receptor agonists reduce the 10-year risk for cardiovascular disease in type 2 diabetes (T2D) patients without baseline CHD, reveals data from real-world study. After 1 year of treatment, a greater percentage of patients discontinued SGLT2i versus GLP1 RA.
The findings of the study are published in the journal Diabetes Research and Clinical Practice.
Ernesto Maddaloni, Sapienza University of Rome, Rome, Italy, and colleagues aimed to evaluate the effect of glucagon-like peptide1 receptor-agonist (GLP1 RA) and sodium-glucose co-transporter2 inhibitor (SGLT2i) on the risk of coronary heart disease (CHD) in type 2 diabetes (T2D) in primary cardiovascular prevention, in this real-world study.
For the purpose, the researchers prospectively collected data from 312 patients with T2D, without CHD history, starting treatment with GLP1 RA (n = 174) or SGLT2i (n = 138). UKPDS-RE score was used for estimating 10-years risk for CHD before and 6, 12 and 24 months after prescription.
Key findings of the study include:
- The 10-year CHD risk significantly decreased over 24 months in both GLP1 RA and SGLT2i groups, with 3% and 7% CHD risk reduction already obtained after the first 6 months of GLP1 RA and SGLT2i therapy respectively in both groups.
- Analyses by categories of baseline CHD risk showed significant reductions of CHD risk in the severe risk categories of both groups.
- CHD risk reduction obtained with SGLT2i was higher than with GLP1 RA at 6 and 12 months but not at 24 months.
"This real-world study shows that both GLP1 RA and SGLT2i reduce the 10-year risk for cardiovascular disease in patients with T2D in primary cardiovascular prevention," wrote the authors.
"Further, the median CHD risk reduction was higher in the SGLT2i compared to the GLP1 RA group at 6 and 12 months."
Reference:
The study titled, "Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention: A 24 months follow-up study," is published in the journal Diabetes Research and Clinical Practice.
DOI: https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(21)00034-6/fulltext
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.